3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Purpura, Thrombotic Thrombocytopenic
1
Purpura, Thrombocytopenic, Idiopathic
1
Neoplasms, Plasma Cell
1
Lymphoma
1
Leukemia
1
COVID-19
1
Interventions
Rituximab
55
Cyclophosphamide
45
Vincristine
23
fludarabine phosphate
21
Cytarabine
20
fludarabine
19
Etoposide
19
Prednisone
18
Bendamustine Hydrochloride
18
ibrutinib
17
Methotrexate
17
Doxorubicin
17
Lenalidomide
15
Radiotherapy
14
Peripheral Blood Stem Cell Transplantation
13
Filgrastim
12
venetoclax
11
Melphalan
11
Dexamethasone
11
Whole-Body Irradiation
8
Tacrolimus
8
Busulfan
8
Brentuximab Vedotin
8
Biopsy
8
pembrolizumab
7
duvelisib
7
Nivolumab
7
Mycophenolic Acid
7
Gemcitabine
7
Cyclosporine
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
ogalvibart
×
Lymphoid
×
Clear all
NCT05393999
2023-04-24
SABRE
Imperial College Healthcare NHS Trust
Phase 2
Withdrawn